F2G bags €50.8m financing to advance olo...UK-Austrian fungal infection specialist F2G Ltd has secured a €50.8m (US $60.8m) financing from new and existing investors. more ➔
Evotec receives $8.4m CARB-X fundingEvotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8.4m funding from CARB-X for co-development of a first-in-class antibiotic. more ➔
The new role of communications in times of...COVID-19 has put life science research companies into the limelight. An Interview with Raimund Gabriel, founder and managing director MC Services AG, on the role of corporate communications in the corona … more ➔
The end of partnering events as we know th...An ongoing crisis and evolving new working habits of industry executives call for an entirely new and up-to-date partnering format. Workarounds such as moving a partnering events scheduled one-on-one … more ➔
BioNTech and Fosun Pharma kick off Chinese...BioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials. more ➔
Evotec partners with Secarna to develop LN...Evotec SE has secured a strategic partnership with Secarna Pharmaceuticals GmbH to co-develop a LNA drug pipeline. more ➔
Rapid test for pandemics Rapid tests have received a lot of attention during the Coronavirus pandemic, but as the number of tests available has increased, so has the confusion around the different types and what they can deliver. … more ➔
EC secures 300 million doses of COVID-19 v...The European Commission has reserved 300 million doses from Sanofi SA/GSK plcs adjuvanted recombinant COVID-19 vaccine. more ➔
Antiviral drugs for pandemic preparedness Viral pandemics are not a once-in-a-lifetime event but a constant threat looming over our heads. While the fight against SARS-CoV-2 is currently a top priority, we should not lose sight of what might … more ➔
Roche’s IL-6 receptor blocker fails...Roche has reported the failure of its IL-6R antagonist tocilizumab in patients with COVID-19 putting the efficacy of IL-6 inhibition at question. more ➔
